Comment on: Changes in immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver.

Wang, Weijie; Wang, Jian

Wang, Weijie; Wang, Jian.

Wang W; State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao; Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang; Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Science, Beijing, China. jack1987168@163.com.
Wang J; Department of Oncology, Luzhou People's Hospital, Luzhou, Sichuan, China.

Clin Exp Rheumatol ; 41(3): 762, 2023 03.

Article in English | MEDLINE | ID: covidwho-2207212

Subject(s)

Antirheumatic Agents; COVID-19; Rheumatic Diseases; Humans; SARS-CoV-2; Antirheumatic Agents/adverse effects; Rheumatic Diseases/drug therapy; Immunosuppressive Agents/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / COVID-19 Limits: Humans Language: English Journal: Clin Exp Rheumatol Year: 2023 Document Type: Article Affiliation country: Clinexprheumatol

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google